BioSpace News Archive

Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, provided an activity report for the third quarter ended March 31, 2023.

CEL-SCI Corporation, a Phase 3 cancer immunotherapy company, announced the pricing of its underwritten confidentially marketed public offering of 794,117 shares of common stock at an offering price of $1.70 per share.

Hillstream BioPharma, Inc. announced the pricing of an underwritten public offering of 5,300,000 shares of its common stock.

AB Science SA summarizes the presentation that was made on masitinib in amyotrophic lateral sclerosis at the American Academy of Neurology 2023 Annual Meeting in Boston, USA.

Avidity Biosciences, Inc. announced positive topline data from the Phase 1/2 MARINA™ clinical trial of AOC 1001 for the treatment of myotonic dystrophy type 1 demonstrating functional improvement, DMPK reduction, splicing improvements and a favorable safety and tolerability profile.

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced the presentation of key data from its Phase 2b multicenter, randomized, double-masked, sham-controlled RESTORE clinical trial (NCT04945772) of MCO-010 at the ARVO annual meeting.

The American Urological Association announced one of their journals, Urology Practice®, has been indexed by MEDLINE.

Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced the Company will release financial results for the first quarter of 2023 after the close of trading on Thursday, May 11, 2023.

Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”) today announced that it will report the Company’s first quarter 2023 financial results on Thursday, May 4, 2023, after the close of the U.S. financial markets.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it will host a conference call at 5:00 p.m. ET on Thursday, May 4, 2023, to discuss its financial results and corporate update for the quarter ending March 31, 2023.